A bill proposed in the House of Representatives would increase oversight of compounding pharmacies, which long-term care operators and other healthcare stakeholders called for after last year's deadly outbreak of meningitis was traced to a compounding pharmacy in Massachusetts.
Last year's tragic and deadly meningitis outbreak left many confused about the differences between compounding pharmacies versus others and what compounded medicine is, as well as the way each are regulated. The information below aims to provide clarity about the terms and their respective practices.
Brought together by the recent outbreak of fungal meningitis, state regulators sought action from the U.S. Food and Drug Administration to regulate compounding pharmacies. The requests came in a Dec. 19 meeting convened by the FDA with representatives from all 50 states.